Alpelisib, an orally bioavailable PI3K inhibitor that selectively targets the p110α isoform, has demonstrated sensitivity in PIK3CA-mutated cancers in preclinical models [34] and in Phase I trials involving patients with advanced solid tumours [43]. Here, PIK3CA is linked to cancer.